

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

| | |
|-------------------------------|---|
| Drug | efinaconazole |
| Brand Name | Jublia™ |
| Dosage Form(s) | Topical solution 10% w/w |
| Manufacturer | Bausch Health, Canada Inc. |
| Submission Type | New Submission |
| Use Reviewed | Jublia™ is used to treat a fungal infection (onychomycosis) caused by certain fungi (<i>Trichophyton species</i>). |
| Common Drug Review (CDR) | Yes, CDR recommended: Do Not Reimburse . Visit the CDR website for more details: www.cadth.ca/node/88649 . www.cadth.ca/sites/default/files/cdr/complete/SR0577%20Jublia%20-%20%20CDEC%20Final%20Recommendation%20May%2027%2C%202019_for%20posting.pdf |
| Drug Benefit Council (DBC) | Efinaconazole (Jublia™) was reviewed internally and was not reviewed by the Drug Benefit Council (DBC) because the CDR recommended not to reimburse Jublia™ for the topical treatment of a fungal infection caused by certain fungi (<i>Trichophyton species</i>). |
| Drug Coverage Decision | Non-Benefit |
| Date | March 3, 2020 |
| Reason(s) | Drug coverage decision is consistent with the CDEC recommendation <ul style="list-style-type: none"> Several medications used to treat onychomycosis are reimbursed by BC PharmaCare, including terbinafine, fluconazole, and itraconazole, and there is no evidence to suggest that topical efinaconazole fulfills an unmet need in treating this condition. Jublia™ did not demonstrate advantages over any comparators used to treat onychomycosis with respect to efficacy, safety and quality of life. |

| | |
|-------------------|--|
| | <ul style="list-style-type: none"> Jublia[™] is a more costly option than other comparators used as first line treatment of onychomycosis. |
| Other Information | None |

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.